Form 4: Nautilus Biotechnology Chief Scientist Parag Mallick Acquires 280,000 Stock Options

Parag Mallick, Chief Scientist at Nautilus Biotechnology, acquired 280,000 stock options on March 1, 2024, according to a recent SEC filing.

Summary

• On March 1, 2024, Parag Mallick, the Chief Scientist of Nautilus Biotechnology, acquired 280,000 stock options.
• The exercise price of these options is $2.72.
• The options vest over time, starting with 25% vesting on January 1, 2025 (one year after the Vesting Commencement Date of January 1, 2024).
• The remaining options vest monthly thereafter over the following 36 months, contingent upon Mallick's continuous service as a 'Service Provider' as defined in the company's 2021 Equity Incentive Plan.
• The options expire on March 1, 2034.

Sentiment

Score: 7

Explanation: The grant of stock options to a key executive is generally a positive sign, indicating alignment of interests and incentivizing long-term commitment. However, it's a routine event and doesn't provide significant new information about the company's prospects.

Positives

• The acquisition of stock options by a key executive like the Chief Scientist can be seen as a positive sign, indicating confidence in the company's future performance.
• The vesting schedule incentivizes the executive to remain with the company for the long term.

Risks

• The vesting of the options is contingent upon continuous service, so any departure of the executive would impact the unvested options.

Industry Context

Stock option grants are a common practice in the biotechnology industry to attract and retain key talent, aligning their interests with those of the shareholders.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for executives in biotech companies, similar to companies like Illumina, Pacific Biosciences, and Bio-Rad Laboratories.
• The vesting schedules are also typical, often tied to continued employment over a period of years.

Stakeholder Impact

• Shareholders may view the stock option grant as a positive incentive for the Chief Scientist to contribute to the company's success.
• Employees may see this as a sign of the company's commitment to its leadership team.

Key Dates